(Press-News.org) Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine (“Insilico”) will present at the 9th LSX World Congress happening in London May 3 and May 4. Zhavoronkov, an expert in generative artificial intelligence (AI) for drug discovery, will present on May 3, 2:45pm (London time) on “‘Death By Pilot’” to Asset Licensing – the Evolution of Pharma-AIDD Partnerships” as part of the Biotech Growth CEO Forum and on May 4, 9:30am (London time) on “Building a Galvanizing & Successful Transatlantic Biotech” as a Biotech Plenary.
The 9th LSX World Congress is Europe’s leading life sciences partnering and investment event, covering therapeutics, devices, digital health, deep technology, and platform technology, and showcases the deep convergence of cutting-edge research and technologies driving the healthcare industry today and in the future. The conference convenes more than 1,500 participants from around the world, including executives and commercial investors from multinational medical and pharmaceutical companies such as Merck, GSK, and Eli Lilly.
Insilico is a leading innovator in advancing new therapeutics using generative AI and reinforcement learning and has developed an end-to-end Pharma.AI platform for identifying novel targets (PandaOmics), designing new drugs (Chemistry42), and predicting the outcomes of clinical trials (InClinico). The platform has produced two drugs that have reached clinical trials. Insilico’s lead drug for the devastating chronic lung disease idiopathic pulmonary fibrosis (IPF), the first AI-discovered and AI-designed drug to advance to clinical trials, will soon be entering Phase 2 trials with patients. And the Company’s generative AI-designed drug for COVID-19 and related variants has been approved for clinical trials and has a number of design advantages over existing COVID-19 drugs.
There are 31 drugs in Insilico’s pipeline available for partnering and licensing for indications including cancer, fibrosis and immunology, and Insilico has partnered with top pharma companies like Fosun and Sanofi to advance their programs.
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases, and aging-related diseases.
For more information, visit www.insilico.com
END
Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents at LSX World Congress
2023-04-28
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Texas Neurologist and Professor elected New American Academy of Neurology President
2023-04-28
MINNEAPOLIS – The American Academy of Neurology (AAN), the world’s largest professional association of neurologists and neuroscience professionals, has elected as its 38th president Carlayne E. Jackson, MD, FAAN, a neurologist, researcher and professor of neurology and otolaryngology at the University of Texas Health Science Center at San Antonio. Jackson succeeds Orly Avitzur, MD, MBA, FAAN, who completed her two-year term as president during the recent AAN Annual Meeting.
“It’s humbling to have been chosen by my colleagues to follow such talented and dedicated individuals ...
First comprehensive care plan to prevent preeclampsia published in the American Journal of Obstetrics and Gynecology
2023-04-28
Recommendations for high-risk expecting parents and health care providers to promote the prevention of preeclampsia, a leading cause of pregnancy-related death in the United States
SAN FRANCISCO - April 28, 2023 – A new special report published in the American Journal of Obstetrics and Gynecology (AJOG) provides a groundbreaking approach to preeclampsia, one of the most pressing issues in maternal health today, and will translate the prediction of risk into prevention of disease.
The report, ...
Max-difference maximization criterion: A feature selection method for text categorization
2023-04-28
For text categorization, it is necessary to select a set of features(terms) with high discrimination by using feature selection. In text feature selection, Accuracy2（ACC2）treats terms with same absolute document rate difference but different discrimination equally, which is unreasonable. Existing improved methods (normalized difference measure（NDM）, max-min ratio（MMR）and trigonometric comparison measure（TCM）) based on ACC2 may confuse the importance of rare and sparse terms on account of challenge for parameter selection.
To solve the problems, a research team led by Li Zhang published their new research on 15 February 2023 in Frontiers of Computer Science co-published ...
U of T receives $200-million grant to support Acceleration Consortium's ‘self-driving labs’ research
2023-04-28
The University of Toronto has been awarded a $200-million grant from the Canada First Research Excellence Fund (CFREF) to revolutionize the speed and impact of scientific discovery through its Acceleration Consortium. The funding – the largest federal research grant ever awarded to a Canadian university – will support the consortium’s work on “self-driving labs” that combine artificial intelligence, robotics and advanced computing to discover new materials and molecules in a fraction of the usual time and cost. Applications include everything from life-saving medications ...
Scientists identify antivirals that could combat emerging infectious diseases
2023-04-28
A new study has identified potential broad-spectrum antiviral agents that can target multiple families of RNA viruses that continue to pose a significant threat for future pandemics. The study, led by Gustavo Garcia Jr. in the UCLA Department of Molecular and Medical Pharmacology, tested a library of innate immune agonists that work by targeting pathogen recognition receptors, and found several agents that showed promise, including one that exhibited potent antiviral activity against members of RNA viral families.
The ongoing SARS-CoV-2 pandemic, which ...
Study finds ChatGTP outperforms physicians in providing high-quality, empathetic advice to patient questions
2023-04-28
La Jolla, Calif. (April 28, 2023) — There has been widespread speculation about how advances in artificial intelligence (AI) assistants like ChatGPT could be used in medicine.
A new study published in JAMA Internal Medicine led by Dr. John W. Ayers from the Qualcomm Institute within the University of California San Diego provides an early glimpse into the role that AI assistants could play in medicine. The study compared written responses from physicians and those from ChatGPT to real-world health questions. A panel of licensed healthcare professionals preferred ChatGPT’s responses 79% of the time and rated ChatGPT’s responses as higher quality ...
Structured exploration allows biological brains to learn faster than AI
2023-04-28
Neuroscientists have uncovered how exploratory actions enable animals to learn their spatial environment more efficiently. Their findings could help build better AI agents that can learn faster and require less experience.
Researchers at the Sainsbury Wellcome Centre and Gatsby Computational Neuroscience Unit at UCL found the instinctual exploratory runs that animals carry out are not random. These purposeful actions allow mice to learn a map of the world efficiently. The study, published today in Neuron, describes how ...
Health care utilization during the pandemic among individuals born preterm
2023-04-28
About The Study: The findings of this study suggest that during the COVID-19 pandemic, children and young adults born preterm were more likely to have used health care related to COVID-19 concerns compared with their term-born peers, independent of a history of bronchopulmonary dysplasia or asthma. Further exploration of factors associated with COVID-19–related health care use may facilitate refinement of care models.
Authors: Elisabeth C. McGowan, M.D., of Brown University in Providence, Rhode Island, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link ...
Comparing physician and AI chatbot responses to patient questions
2023-04-28
About The Study: In this study of 195 randomly drawn patient questions from a social media forum, a team of licensed health care professionals compared physician’s and chatbot’s responses. The chatbot responses were preferred over physician responses and rated significantly higher for both quality and empathy. Further exploration of this technology is warranted in clinical settings, such as using chatbot to draft responses that physicians could then edit. Randomized trials could assess further if using AI assistants might ...
Treatment of children with ADHD
2023-04-28
About The Study: The results of this study of children with parent-reported attention-deficit/hyperactivity disorder (ADHD) suggest that most were not receiving ADHD medications and had never received outpatient mental health care. Gaps in treatment, which were not directly associated with socioeconomic disadvantage, underscore the challenges of improving communication and access to outpatient mental health care for children with ADHD.
Authors: Mark Olfson, M.D., M.P.H., of Columbia University and the New York State Psychiatric ...